Yaşa Bağlı Maküler Dejenerasyonda Gözlenen Geografik Atrofiye Yönelik Güncel Tedaviler

Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901 DOI 10.1001/jama.291.15.1900

Chew EY, Clemons TE, Agron E, Sperduto RD, Sangiovanni JP, Davis MD, Ferris FL, 3rd, Age-Related Eye Disease Study Research G (2014) Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol 132: 272-277 DOI 10.1001/jamaophthalmol.2013.6636

Age-Related Eye Disease Study Research G (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107: 2224-2232 DOI 10.1016/s0161-6420(00)00409-7

Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A (2019) Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci 20 DOI 10.3390/ijms20071693

Group AR, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL (2012) The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 119: 2282-2289 DOI 10.1016/j.ophtha.2012.05.027

Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG (2020) Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology 127: 186-195 DOI 10.1016/j.ophtha.2019.07.011

Shughoury A, Sevgi DD, Ciulla TA (2023) The complement system: a novel therapeutic target for age-related macular degeneration. Expert Opin Pharmacother 24: 1887-1899 DOI 10.1080/14656566.2023.2257604

Patel SB, Heier JS, Chaudhary V, Wykoff CC (2023) Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol DOI 10.1097/ICU.0000000000000845

Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Mones J, Singh RP, Ribeiro R, Wykoff CC, Oaks, investigators Ds (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402: 1434-1448 DOI 10.1016/S0140-6736(23)01520-9

Suner IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM (2009) Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 50: 3629-3635 DOI 10.1167/iovs.08-3225

Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM (2023) Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond) 37: 3551-3557 DOI 10.1038/s41433-023-02497-w

Li AS, Myers J, Stinnett SS, Grewal DS, Jaffe GJ (2024) Gradeability and Reproducibility of Geographic Atrophy Measurement in GATHER-1, a Phase II/III Randomized Interventional Trial. Ophthalmol Sci 4: 100383 DOI 10.1016/j.xops.2023.100383

Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ, investigators Gt (2023) Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402: 1449-1458 DOI 10.1016/S0140-6736(23)01583-0

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T (2023) Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates. Invest Ophthalmol Vis Sci 64: 3 DOI 10.1167/iovs.64.2.3

Sun Y, Wirta D, Murahashi W, Mathur V, Sankaranarayanan S, Taylor LK, Yednock T, Fong DS, Goldberg JL (2023) Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci 3: 100290 DOI 10.1016/j.xops.2023.100290

Kassa E, Ciulla TA, Hussain RM, Dugel PU (2019) Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther 19: 335-342 DOI 10.1080/14712598.2019.1575358

Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK (2022) Review of gene therapies for age-related macular degeneration. Eye (Lond) 36: 303-311 DOI 10.1038/s41433-021-01842-1

Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL (2023) Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev 313: 402-419 DOI 10.1111/imr.13149

Borchert GA, Shamsnajafabadi H, Hu ML, De Silva SR, Downes SM, MacLaren RE, Xue K, Cehajic-Kapetanovic J (2023) The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy. Cells 12 DOI 10.3390/cells12162092

Freeman WR, Bandello F, Souied E, Guymer RH, Garg SJ, Chen FK, Rich R, Holz FG, Patel SS, Kim K, Lopez FJ, Group BS (2023) Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina 7: 573-585 DOI 10.1016/j.oret.2023.03.001

Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901 DOI 10.1001/jama.291.15.1900

Chew EY, Clemons TE, Agron E, Sperduto RD, Sangiovanni JP, Davis MD, Ferris FL, 3rd, Age-Related Eye Disease Study Research G (2014) Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol 132: 272-277 DOI 10.1001/jamaophthalmol.2013.6636

Age-Related Eye Disease Study Research G (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107: 2224-2232 DOI 10.1016/s0161-6420(00)00409-7

Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A (2019) Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci 20 DOI 10.3390/ijms20071693

Group AR, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL (2012) The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 119: 2282-2289 DOI 10.1016/j.ophtha.2012.05.027

Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG (2020) Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology 127: 186-195 DOI 10.1016/j.ophtha.2019.07.011

Shughoury A, Sevgi DD, Ciulla TA (2023) The complement system: a novel therapeutic target for age-related macular degeneration. Expert Opin Pharmacother 24: 1887-1899 DOI 10.1080/14656566.2023.2257604

Patel SB, Heier JS, Chaudhary V, Wykoff CC (2023) Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol DOI 10.1097/ICU.0000000000000845

Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Mones J, Singh RP, Ribeiro R, Wykoff CC, Oaks, investigators Ds (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402: 1434-1448 DOI 10.1016/S0140-6736(23)01520-9

Suner IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM (2009) Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 50: 3629-3635 DOI 10.1167/iovs.08-3225

Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM (2023) Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond) 37: 3551-3557 DOI 10.1038/s41433-023-02497-w

Li AS, Myers J, Stinnett SS, Grewal DS, Jaffe GJ (2024) Gradeability and Reproducibility of Geographic Atrophy Measurement in GATHER-1, a Phase II/III Randomized Interventional Trial. Ophthalmol Sci 4: 100383 DOI 10.1016/j.xops.2023.100383

Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ, investigators Gt (2023) Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402: 1449-1458 DOI 10.1016/S0140-6736(23)01583-0

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T (2023) Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates. Invest Ophthalmol Vis Sci 64: 3 DOI 10.1167/iovs.64.2.3

Sun Y, Wirta D, Murahashi W, Mathur V, Sankaranarayanan S, Taylor LK, Yednock T, Fong DS, Goldberg JL (2023) Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci 3: 100290 DOI 10.1016/j.xops.2023.100290

Kassa E, Ciulla TA, Hussain RM, Dugel PU (2019) Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther 19: 335-342 DOI 10.1080/14712598.2019.1575358

Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK (2022) Review of gene therapies for age-related macular degeneration. Eye (Lond) 36: 303-311 DOI 10.1038/s41433-021-01842-1

Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL (2023) Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev 313: 402-419 DOI 10.1111/imr.13149

Borchert GA, Shamsnajafabadi H, Hu ML, De Silva SR, Downes SM, MacLaren RE, Xue K, Cehajic-Kapetanovic J (2023) The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy. Cells 12 DOI 10.3390/cells12162092

Freeman WR, Bandello F, Souied E, Guymer RH, Garg SJ, Chen FK, Rich R, Holz FG, Patel SS, Kim K, Lopez FJ, Group BS (2023) Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina 7: 573-585 DOI 10.1016/j.oret.2023.03.001